Search

Your search keyword '"Munro, Alison F."' showing total 37 results

Search Constraints

Start Over You searched for: Author "Munro, Alison F." Remove constraint Author: "Munro, Alison F."
37 results on '"Munro, Alison F."'

Search Results

5. A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials

6. A targetable PREX2/RAC1/PI3Kβ signalling axis confers resistance to clinically relevant therapeutic approaches in melanoma

10. Unlocking the transcriptomic potential of formalin-fixed paraffin embedded clinical tissues: comparison of gene expression profiling approaches

11. Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability

12. Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability

15. Multiparametric High-Content Cell Painting Identifies Copper Ionophores as Selective Modulators of Esophageal Cancer Phenotypes

17. A novel mode of inhibiting SRC improves drug efficacy and tolerability

18. High-content profiling reveals a unified model of copper ionophore dependent cell death in oesophageal adenocarcinoma

22. A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability

23. A conformation selective mode of inhibiting SRC improves drug efficacy and tolerability

25. Supplemental_Material_for__high_content_phenotypic_profiling_by_Hughes,_et_al – Supplemental material for High-Content Phenotypic Profiling in Esophageal Adenocarcinoma Identifies Selectively Active Pharmacological Classes of Drugs for Repurposing and Chemical Starting Points for Novel Drug Discovery

28. Rapid Discovery and Structure–Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase

29. Predicting Anthracycline Benefit: TOP2A and CEP17—Not Only but Also

31. Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?

34. The p160 ER co-regulators predict outcome in ER negative breast cancer

37. Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma.

Catalog

Books, media, physical & digital resources